Invesco LLC slashed its Amgen holdings by 20.2%, unloading 2,310 shares worth roughly $2.85 million. This sale brought ...

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...

Amgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Oppenheimer & Co. Inc. trimmed its stake in Amgen Inc. by 1.2% in Q1, selling 1,335 shares, bringing its holding to 109,833 ...

Shares of Amgen (AMGN) fell on Monday after announcing that its weight-loss drug will move into a phase 3 trial, with ...

In the most recent trading session, Amgen (AMGN) closed at $280.35, indicating a +1.03% shift from the previous trading day.

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...